Stockscreener 앱 받기
52.37
0.06%
-0.03
시간 외 거래:
52.36
-0.010
-0.02%
Moderna Inc 주식(MRNA)의 최신 뉴스
Why Moderna (MRNA) Is Down 6.4% After Cancer Vaccine Data And Flu Shot’s Expedited FDA Review - Yahoo Finance UK
Pfizer vs Moderna 2026: Pipeline Prospects After Vaccine Sales DropNews and Statistics - IndexBox
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Globe and Mail
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Motley Fool
Moderna shares see a dip: what is pressuring the stock - Traders Union
Moderna shares see a jump — What is fueling the stock rise - Traders Union
Federal Judge Blocks RFK Jr. Vaccine Policy Shift: Spikevax's Path Forward Stabilized - AD HOC NEWS
Militia Capital Partners LP Sells 49,000 Shares of Moderna, Inc. $MRNA - MarketBeat
Times Opinion: An erratic FDA is a threat to innovation - Chattanooga Times Free Press
Moderna says CEO Stéphane Bancel's 2025 total compensation was $19.9 millionSEC filing - marketscreener.com
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery - FinancialContent
Form DEFA14A Moderna, Inc. - StreetInsider
US Health Secretary Kennedy's vaccine actions and policy positions - marketscreener.com
Moderna Clears Legal Hurdle and Advances Vaccine Pipeline - AD HOC NEWS
Moderna (MRNA) Is Down 5.7% After Costly LNP Settlement And Multi-Pathogen Trial UpdateHas The Bull Case Changed? - simplywall.st
An erratic FDA is a threat to innovation - The Korea Times
Moderna, Inc. Trade Ideas — EUROTLX:4MRNA - TradingView
Moderna to pay about $1 billion to settle Arbutus litigation - MSN
Moderna (MRNA) Valuation Check As Multi Pathogen mRNA Study Completion And FDA Shifts Draw Fresh Focus - Yahoo Finance
Moderna Impfstoff Spikevax 2025-2026: What Changed This Year - AD HOC NEWS
Moderna Impfstoff (Spikevax) in 2026: Key Updates - AD HOC NEWS
Moderna (MRNA) Valuation Check After Sharp Multi‑Month Share Price Rebound - simplywall.st
Moderna Impfstoff (Spikevax): What Changed in 2026 - AD HOC NEWS
Moderna (MRNA) Declines More Than Market: Some Information for Investors - Yahoo Finance
Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits - JD Supra
Why is Moderna stock down today? - Traders Union
3 Healthcare Stocks to Avoid in 2026: Analysis of UnderperformersNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Moderna Valuation Questioned As mRNA Guidance And Flu Review Shift - simplywall.st
Moderna’s Spikevax update: What US patients really need to know now - AD HOC NEWS
Moderna, Inc. $MRNA Position Increased by Theleme Partners LLP - MarketBeat
An Erratic FDA Is a Threat to Innovation - Bloomberg.com
Moderna operates through several specialized therapeutic “pillars”: - WhatJobs
FDA declines to review Moderna's mRNA flu shot - MSN
Moderna (MRNA) and BioNTech (BNTX) Shares Rise on Advisory Rever - GuruFocus
Moderna Settles Patent Litigation with Arbutus et al. - JD Supra
Is It Too Early To Reassess Moderna (MRNA) After Its Strong 2024 Share Price Rally? - simplywall.st
Jefferies Financial Group Reduces Moderna Stake - National Today
Jefferies Financial Group Inc. Sells 32,310 Shares of Moderna, Inc. $MRNA - MarketBeat
US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports - Reuters
Moderna: Pipeline Hope Won't Pay The Bills (NASDAQ:MRNA) - Seeking Alpha
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna Stock Hits Day High with 6.13% Surge, Outperforming S&P 500 - Markets Mojo
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks - Intellectia AI
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX) - Seeking Alpha
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Lyme Disease Vaccine Market Is Booming So Rapidly | Valneva SE • Pfizer Inc. • Moderna Inc - openPR.com
Quantbot Technologies LP Sells 34,481 Shares of Moderna, Inc. $MRNA - MarketBeat
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Bitget
MRNA Stock Quote Price and Forecast - CNN
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Moderna surges after hours on patent settlement with Arbutus and Genevant - MSN
Is Moderna (MRNA) Pricing Too High After Its Recent 70% Year To Date Rally - Yahoo Finance
Moderna Settlement And EMA Opinion Reframe mRNA Platform Outlook - finance.yahoo.com
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - Lubbock Avalanche-Journal
Is Moderna Inc. stock attractive after correction2026 Major Catalysts & Long-Term Growth Stock Strategies - Naître et grandir
Aug Highlights: Why Moderna Inc. stock appeals to analystsTrade Entry Report & Weekly Stock Performance Updates - Naître et grandir
Moderna Stock (MRNA) Opinions on FDA Vaccines Chief Departure | MRNA Stock News - Quiver Quantitative
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
Moderna (MRNA) Chief Legal Officer logs RSU conversion and tax share disposition - Stock Titan
Market Watch Rx: IQVIA Joins Top Gainers - Pharmaceutical Executive
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz
Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Stock Price Down 7.6%Here's What Happened - MarketBeat
EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug - RTTNews
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology - FinancialContent
These 3 Stocks Just Bounced From Lows — What Wall Street Thinks Comes Next - 24/7 Wall St.
0.00%
0.77%
자본화:
|
볼륨(24시간):